Elixir Medical, a company dedicated to developing innovative treatments for cardiovascular diseases, has released promising data from its INFINITY-SWEDEHEART trial. This trial compares the effectiveness of their DynamX® Coronary Bioadaptor System to the standard Resolute Onyx™ zotarolimus drug-eluting stent (DES) in a diverse group of patients undergoing percutaneous coronary intervention (PCI).
The findings, presented at the Transcatheter Cardiovascular Therapeutics® (TCT®) conference and published in The Lancet, highlight the bioadaptor’s significant advantages, particularly for high-risk patient groups. These include individuals with acute coronary syndrome (ACS), small vessel lesions, and blockages in the left anterior descending (LAD) artery. Traditionally, these patients face a heightened risk of complications following PCI due to factors like existing health conditions and weaker heart function.
Data from the INFINITY-SWEDEHEART trial showed that patients with ACS who received the bioadaptor experienced a marked decrease in major adverse cardiac events compared to those who received the DES. This reduction in adverse events was sustained after the six-month mark, a significant finding considering the typical increase in event rates observed with traditional stents over time. Similar positive outcomes were observed in LAD artery and small vessel disease patients.
The bioadaptor’s success stems from its unique design, which allows it to adapt to the body’s natural movements and promote healthy blood flow. Unlike rigid stents, the bioadaptor’s helical strands unlock after six months, providing dynamic support and enabling the treated blood vessel to function more naturally. This approach addresses a crucial limitation of existing stent technologies – the inability to restore normal vessel function.
Elixir Medical believes the bioadaptor represents a major advancement in coronary artery disease (CAD) treatment. By restoring natural vessel function, the bioadaptor offers a promising solution for long-term success in managing CAD, particularly for high-risk patients. This technology holds the potential to significantly improve the lives of countless individuals battling this prevalent disease.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
